Entera Bio Statistics
Total Valuation
Entera Bio has a market cap or net worth of $60.04 million. The enterprise value is $53.12 million.
Important Dates
The last earnings date was Friday, March 28, 2025, after market close.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Entera Bio has 36.83 million shares outstanding. The number of shares has increased by 29.79% in one year.
| Current Share Class | 36.83M |
| Shares Outstanding | 36.83M |
| Shares Change (YoY) | +29.79% |
| Shares Change (QoQ) | +3.89% |
| Owned by Insiders (%) | 2.33% |
| Owned by Institutions (%) | 4.42% |
| Float | 21.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 339.83 |
| Forward PS | n/a |
| PB Ratio | 8.17 |
| P/TBV Ratio | 7.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 293.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.63, with a Debt / Equity ratio of 0.03.
| Current Ratio | 7.63 |
| Quick Ratio | 7.47 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -103.34% and return on invested capital (ROIC) is -62.64%.
| Return on Equity (ROE) | -103.34% |
| Return on Assets (ROA) | -56.64% |
| Return on Invested Capital (ROIC) | -62.64% |
| Return on Capital Employed (ROCE) | -116.69% |
| Revenue Per Employee | $10,056 |
| Profits Per Employee | -$530,056 |
| Employee Count | 18 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Entera Bio has paid $14,000 in taxes.
| Income Tax | 14,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.80% in the last 52 weeks. The beta is 1.63, so Entera Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.63 |
| 52-Week Price Change | -1.80% |
| 50-Day Moving Average | 2.11 |
| 200-Day Moving Average | 1.94 |
| Relative Strength Index (RSI) | 31.16 |
| Average Volume (20 Days) | 46,733 |
Short Selling Information
| Short Interest | 86,138 |
| Short Previous Month | 99,787 |
| Short % of Shares Out | 0.23% |
| Short % of Float | 0.41% |
| Short Ratio (days to cover) | 1.51 |
Income Statement
In the last 12 months, Entera Bio had revenue of $181,000 and -$9.54 million in losses. Loss per share was -$0.25.
| Revenue | 181,000 |
| Gross Profit | 9,000 |
| Operating Income | -9.59M |
| Pretax Income | -8.51M |
| Net Income | -9.54M |
| EBITDA | -9.54M |
| EBIT | -9.59M |
| Loss Per Share | -$0.25 |
Full Income StatementBalance Sheet
The company has $8.66 million in cash and $272,000 in debt, giving a net cash position of $8.39 million or $0.23 per share.
| Cash & Cash Equivalents | 8.66M |
| Total Debt | 272,000 |
| Net Cash | 8.39M |
| Net Cash Per Share | $0.23 |
| Equity (Book Value) | 8.08M |
| Book Value Per Share | 0.21 |
| Working Capital | 7.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.82 million and capital expenditures -$3,000, giving a free cash flow of -$6.82 million.
| Operating Cash Flow | -6.82M |
| Capital Expenditures | -3,000 |
| Free Cash Flow | -6.82M |
| FCF Per Share | -$0.19 |
Full Cash Flow StatementMargins
| Gross Margin | 4.97% |
| Operating Margin | -5,295.58% |
| Pretax Margin | -5,263.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |